Africa-Humanwell Healthcare (Group) Co.-Humanwell Healthcare (Group) Co.

Global

CURRENT LOCATION: HOME > Global > Africa

Global

Adhere to the strategy of R&D innovation and international expansion; accelerate the research and development of innovative drug projects in core areas; promote the development and listing of characteristic generic drugs around product lines; continuously enrich the product lines; actively expand mature markets in Europe and the United States, as well as emerging markets in Africa, Central Asia and Southeast Asia.

ASIA PACIFIC

Humanwell is one of China's leading pharmaceutical companies, competing with both domestic and multinational corporations. We have established dominant market positions in several therapeutic areas: over 60% market share in anesthetics/analgesics and more than 50% in Uyghur medicine (one subset of Chinese traditional medicine), making us the undisputed leader in these market segments. We also command a leading position in fertility regulation drugs with over 30% market share. Through our expanding portfolio of high-value products, we are steadily progressing toward our goal of remaining a top pharmaceutical company in China.

Our robust commercial infrastructure with a professional sales team of 6,000 representatives, enables comprehensive market coverage across China. Our extensive distribution network reaches 10,000 hospitals and 30,000 pharmacies nationwide.

NORTH AMERICA

Humanwell’s North American expansion started in 2008, with the establishment of PuraCap Pharmaceutical in New Jersey. PuraCap specializes in research and development, manufacturing, and commercialization of soft gel prescription generic and OTC products. With its headquarters, R&D team, and sales and marketing team in New Jersey, its state-of-the-art cGMP manufacturing facility (soft gel capacity of up to 6 billion capsules annually) in Wuhan, and expansion to 12 billion capsules annually in next few years, and total employees of 500+, PuraCap supplies major US wholesalers and pharmacy chains with more than 200 products carrying major and store brands.

Humanwell acquired Epic Pharma, LLC in 2016. Epic is a leader in R&D, manufacturing, and commercialization of diversity dosage form products and controlled substance prescription generics drugs in the US. Located in New York with 230 employees, Epic manufactures high quality prescription generics on behalf of its pharmaceutical clients such as Sandoz, and supplies to major wholesalers and group purchase organizations (GPOs) prescription generics under its own label. In addition to a total of 40 marketed products, the company owns a pipeline with 230 ANDAs, 12 filed to the FDA with pending approvals, and 10 in late stage development.

AFRICA

Humanwell expanded its presence into Africa to provide equitable healthcare solutions to a region with tremendous unmet medical needs, but historically under-served by the global pharmaceutical industry. The company established Humanwell Pharma Mali S.A. in 2009 to specifically serve the Economic Community of West Africa States (ECOWAS) countries.

In 2015, in cooperation with the China-Africa Development Fund, Humanwell (Africa) Pharmaceutical S.A. was built as a manufacturing facility under the current GMP standard to meet the tremendous needs of essential drugs in Africa, and this GMP standard was recognized by the national government of Mali as the medical industry standard. The facility was the first of its kind in Mali and West Africa, and has become the main supplier of local government procurement, and provides medicines in a large number of local hospitals, clinics, and pharmacies.

In 2017, Humanwell invested in its second manufacturing facility in Africa to serve patients in East African countries, which was completed in 2018 in Ethiopia, and it passed the inspection of the Ethiopian Drug Regulatory Authority, obtaining the first GMP certificate as a local pharmaceutical enterprise in Ethiopia. At present, Humanwell Ethiopia is ranked among the top 3 local pharmaceutical companies in terms of the drug approvals in Ethiopia.

EUROPE

In 2024, Humanwell strategically expanded into Europe through the acquisition of Paion, a German specialty pharmaceutical company founded in 2000 in Aachen. Paion specializes in innovative therapeutics for hospital-based sedation, anesthesia, and critical care services.

Paion's European portfolio also includes three products:

Byfavo® (remimazolam): the company's flagship product, is an innovative ultra-short-acting benzodiazepine sedative/anesthetic administered intravenously, offering precise control in clinical settings. Currently, Byfavo® is being launched across select European markets while maintaining strategic partnerships for commercialization in various territories worldwide.

GIAPREZA® (Angiotensin II): A vasoconstrictor for treating refractory hypotension in adult patients with septic or other distributive shock.

XERAVA® (eravacycline): A next-generation fluorocycline antibiotic developed for complicated intra-abdominal infections in adults.

As part of Humanwell family, Paion continues its mission to advance patient care in anesthesia and critical care through innovative pharmaceutical solutions, serving the needs of healthcare professionals and patients across Europe.

China

Wuhan PuraCap Production Base for Export (Wuhan PuraCap)

It is the first manufacturer of soft capsule in Hubei Province approved by US FDA certification, the leading supplier of soft capsule drug preparations in the US market, and the leading enterprise in R&D and production of soft capsule drug preparations in the world.

Humanwell Likang Production Base for Oral Solid Preparations (Humanwell Likang)

The company has dual qualifications by NMPA and FDA. Its production range covers injections and high-end oral solid preparations. It can undertake the production commission of the full process from clinical samples to commercialized production.

Yichang Humanwell Production Base for Export

The company is the first factory for oral solid preparations in Hubei Province that has been certified by the US FDA and the UK MHRA. The company's business focuses on the research and development, registration, production and international sales of sustained-release and controlled-release oral solid preparations and generic drugs of transdermal preparations which meet national standards.

Uzbekistan

Xinjiang Xipa Pharmaceuticals

Established as a subsidiary in the Republic of Uzbekistan in 2016, formed a professional market academic promotion team and registration team, registered six Uyghur medicines, and sales cover the entire territory of Uzbekistan.